Who was studied?
Adults with obesity without diabetes received retatrutide or placebo. Subgroups had knee osteoarthritis or obstructive sleep apnea.
- Participants
- 2,339 adults
- Duration
- 80 weeks
- Funding
- Eli Lilly
What did the study find?
Average weight reduction at 12 mg was 25.0%, versus 3.9% with placebo, using the treatment-regimen estimand. Pain and apnea outcomes also improved in the respective subgroups.
What should you keep in mind?
Gastrointestinal events were most common. Subgroup outcomes and weight outcomes used different analysis strategies.
Why it matters
Read the analysis method beside each headline. Trial results do not constitute regulatory approval.
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Published 2026 · PMID 42814954 · DOI 10.1056/NEJMoa2604169
Summary by Peptide Lit, checked against the original abstract on October 7, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.